Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 671-682

  Zamarrón, Carlos ^a   Paz, Vanesa García ^a   Morete, Emilio ^a   Matías, Felix del Campo ^b  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Cardiovascular disease; Chronic obstructie pulmonary disease; Obstructive sleep apnea syndrome; Overlap syndrome; Sleep

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL OXYGEN SATURATION; BLOOD OXYGEN TENSION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DYSPNEA; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERCAPNIA; LUNG VENTILATION; OXYGEN THERAPY; POLYSOMNOGRAPHY; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; SLEEP APNEA SYNDROME; SLEEP PATTERN; SPUTUM; SPUTUM PRODUCTION; WAKEFULNESS;

ANOXIA; CARDIOVASCULAR DISEASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; HYPERCAPNIA; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 60249090340     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Agusti AG, Noguera A, Sauleda J, et al. 2003. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J, 21:347-60.
2. Agusti AG. 2005. COPD, a multicomponent disease: implications for management. Respir Med, 99:670-82.
3. Ambrosino N, Strambi S. 2004. New strategies to improve exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J, 24:313-22.
4. Andreas S, Anker SD, Scanlon PD, et al. 2005. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest, 128:3618-24.
5. Andreassen H, Vestbo J. 2003. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J Suppl, 46:2-4.
6. Badr MS. 1999. Pathogenesis of obstructive sleep apnea. Prog Cardiovasc Dis, 41:323-30.
7. Bady E, Achkar A, Pascal S, et al. 2000. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax, 55:934-9.
8. Ballard RD, Clover CW, Suh BY. 1995. Influence of sleep on respiratory function in emphysema. Am J Respir Crit Care Med, 151:945-51.
9. Ballard RD, Irvin CG, Martin RJ, et al. 1990. Influence of sleep on lung volume in asthmatic patients and normal subjects. J Appl Physiol, 68:2034-41.
10. Barcelo A, Barbe F, Llompart E, et al. 2005. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med, 171:183-7.
11. Basner RC, Ringler J, Schwartzstein RM, et al. 1991. Phasic electromyographic activity of the genioglossus increases in normals during slow-wave sleep. Respir Physiol, 83:189-200.
12. Becker HF, Jerrentrup A, Ploch T, et al. 2003. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation, 107:68-73.
13. Becker HF, Piper AJ, Flynn WE, et al. 1999. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med, 159:112-8.
14. Bednarek M, Plywaczewski R, Jonczak L, et al. 2005. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population study. Respiration, 72:142-9.
15. Bellia V, Catalano F, Scichilone N, et al. 2003. Sleep disorders in the elderly with and without chronic airflow obstruction: the SARA study. Sleep, 26:318-23.
16. 2 with long-term CPAP therapy for obstructive sleep apnea. Am Rev Respir Dis, 135:144-7.
17. Berthon-Jones M, Sullivan CE. 1984. Ventilation and arousal responses to hypercapnia in normal sleeping humans. J Appl Physiol, 57:59-67.
18. Block AJ, Boysen PG, Wynne JW, et al. 1979. Sleep apnea, hypopnea and oxygen desaturation in normal subjects. A strong male predominance. N Engl J Med, 300:513-7.
19. Bonsignore MR, Marrone O, Insalaco G, et al. 1994. The cardiovascular effects of obstructive sleep apnoeas: analysis of pathogenic mechanisms. Eur Respir J, 7:786-805.
20. Bradley TD. 1992. Right and left ventricular functional impairment and sleep apnea. Clin Chest Med, 13:459-79.
21. Brezinova V, Catterall JR, Douglas NJ, et al. 1982. Night sleep of patients with chronic ventilatory failure and age matched controls: number and duration of the EEG episodes of intervening wakefulness and drowsiness. Sleep, 5:123-30.
22. Broekhuizen R, Wouters EF, Creutzberg EC, et al. 2006. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax, 61:17-22.
23. Bryan AC, Muller NL. 1980. Lung mechanics and gas exchange during sleep. Sleep, 3:401-6.
24. Calverley PM, Brezinova V, Douglas NJ, et al. 1982. The effect of oxygenation on sleep quality in chronic bronchitis and emphysema. Am Rev Respir Dis, 126:206-10.
25. Camilli AE, Robbins DR, Lebowitz MD. 1991. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol, 133:795-800.
26. Carpagnano GE, Kharitonov SA, Resta O, et al. 2002. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest, 122:1162-7.
27. Catterall JR, Calverley PM, MacNee W, et al. 1985. Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema. J Appl Physiol, 59:1698-703.
28. Celermajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340:1111-5.
29. Cella G, Sbarai A, Mazzaro G, et al. 2001. Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost, 7:205-8.
30. Celli BR, MacNee W. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
31. Chan CS, Bye PT, Woolcock AJ, et al. 1990. Eucapnia and hypercapnia in patients with chronic airflow limitation. The role of the upper airway. Am Rev Respir Dis, 141:861-5.
32. Chaouat A, Bugnet AS, Kadaoui N, et al. 2005. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 172:189-94.
33. 2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Eur Respir J, 10:1730-5.
34. Chaouat A, Weitzenblum E, Krieger J, et al. 1995. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med, 151:82-6.
35. Chaouat A, Weitzenblum E, Krieger J, et al. 1996. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest, 109:380-6.
36. Chin K, Nakamura T, Shimizu K, et al. 2000. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med, 109:562-7.
37. Clausen JL. 1990. The diagnosis of emphysema, chronic bronchitis, and asthma. Clin Chest Med, 11:405-16.
38. Colt HG, Haas H, Rich GB. 1991. Hypoxemia vs sleep fragmentation as cause of excessive daytime sleepiness in obstructive sleep apnea. Chest, 100:1542-8.
39. Cormick W, Olson LG, Hensley MJ, et al. 1986. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax, 41:846-54.
40. Cortelli P, Parchi P, Sforza E, et al. 1994. Cardiovascular autonomic dysfunction in normotensive awake subjects with obstructive sleep apnoea syndrome. Clin Auton Res, 4:57-62.
41. De Miguel J, Cabello J, Sanchez-Alarcos JM, et al. 2002. Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome. Sleep Breath, 6:3-10.
42. Deegan PC, McNicholas WT. 1995. Pathophysiology of obstructive sleep apnoea. Eur Respir J, 8:1161-78.
43. Deegan PC, McNicholas WT. 1996. Predictive value of clinical features for the obstructive sleep apnoea syndrome. Eur Respir J, 9:117-24.
44. Douglas NJ, Flenley DC. 1990. Breathing during sleep in patients with obstructive lung disease. Am Rev Respir Dis, 141:1055-70.
45. Douglas NJ, White DP, Pickett CK, et al. 1982a. Respiration during sleep in normal man. Thorax, 37:840-4.
46. Douglas NJ, White DP, Weil JV, et al. 1982b. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis, 126:758-62.
47. Douglas NJ. 1985. Control of ventilation during sleep. Clin Chest Med, 6:563-75.
48. Duran J, Esnaola S, Rubio R, et al. 2001. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med, 163:685-9.
49. Dyugovskaya L, Lavie P, Lavie L. 2002. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med, 165:934-9.
50. Easton PA, West P, Meatherall RC, et al. 1987. The effect of excessive ethanol ingestion on sleep in severe chronic obstructive pulmonary disease. Sleep, 10:224-33.
51. El Bayadi S, Millman RP, Tishler PV, et al. 1990. A family study of sleep apnea. Anatomic and physiologic interactions. Chest, 98:554-9.
52. Elliott MW, Mulvey DA, Moxham J, et al. 1991. Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions. Eur Respir J, 4:1044-52.
53. El-Solh AA, Mador MJ, Sikka P, et al. 2002. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest, 121:1541-7.
54. Erbland ML, Ebert RV, Snow SL. 1990. Interaction of hypoxia and hypercapnia on respiratory drive in patients with COPD. Chest, 97:1289-94.
55. Faulkner MA, Hilleman DE. 2003. Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy, 23:1300-15.
56. Flenley DC. 1985. Sleep in chronic obstructive lung disease. Clin Chest Med, 6:651-61.
57. Fleetham J, West P, Mezon B, et al. 1982. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis, 126:429-33.
58. Flemons WW, Douglas NJ, Kuna ST, et al. 2004. Access to diagnosis and treatment of patients with suspected sleep apnea. Am J Respir Crit Care Med, 169:668-72.
59. Flemons WW. 2002. Clinical practice. Obstructive sleep apnea. N Engl J Med, 347:498-504.
60. Fletcher EC, Levin DC. 1984. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest, 85:6-14.
61. Fogel RB, Malhotra A, White DP. 2004. Sleep. 2: pathophysiology of obstructive sleep apnoea/hypopnoea syndrome. Thorax, 59:159-63.
62. Francis GS, McDonald KM, Cohn JN. 1993. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation, 87:90-6.
63. Gan WQ, Man SF, Senthilselvan A, et al. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 59:574-80.
64. Garay SM, Rapoport D, Sorkin B, et al. 1981. Regulation of ventilation in the obstructive sleep apnea syndrome. Am Rev Respir Dis, 124:451-7.
65. Gastaut H, Tassinari CA, Duron B. 1965. Polygraphic study of diurnal and nocturnal (hypnic and respiratory) episodal manifestations of Pickwick syndrome. Rev Neurol (Paris), 112:568-79.
66. Giles TL, Lasserson TJ, Smith BJ, et al. 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev, CD001106.
67. Godoy I, Campana AO, Geraldo RR, et al. 2003. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur Respir J, 22:920-5.
68. Goldbart AD, Krishna J, Li RC, et al. 2006. Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome. Chest, 130:143-8.
69. Goldstein RS, Ramcharan V, Bowes G, et al. 1984. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med, 310:425-9.
70. Guilleminault C, Cummiskey J, Motta J. 1980. Chronic obstructive airflow disease and sleep studies. Am Rev Respir Dis, 122:397-406.
71. Guilleminault C, Tilkian A, Dement WC. 1976. The sleep apnea syndromes. Ann Rev Med, 27:465-84.
72. Guilleminault C. 1985. Obstructive sleep apnea. The clinical syndrome and historical perspective. Med Clin North Am, 69:1187-203.
73. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352:1685-95.
74. Harsch IA, Konturek PC, Koebnick C, et al. 2003. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J, 22:251-7.
75. Hatipoglu U, Rubinstein I. 2003. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration, 70:665-71.
76. Hawrylkiewicz I, Sliwinski P, Gorecka D, et al. 2004. Pulmonary haemodynamics in patients with OSAS or an overlap syndrome. Monaldi Arch Chest Dis, 61:148-52.
77. Haynes PL. 2005. The role of behavioral sleep medicine in the assessment and treatment of sleep disordered breathing. Clin Psychol Rev, 25:673-705.
78. Heijdra YF, Dekhuijzen PN, van Herwaarden CL, et al. 1995. Nocturnal saturation and respiratory muscle function in patients with chronic obstructive pulmonary disease. Thorax, 50:610-2.
79. Hudgel DW, Devadatta P. 1984. Decrease in functional residual capacity during sleep in normal humans. J Appl Physiol, 57:1319-22.
80. Hudgel DW, Gordon EA, Thanakitcharu S, et al. 1998. Instability of ventilatory control in patients with obstructive sleep apnea. Am J Respir Crit Care Med, 158:1142-9.
81. Hudgel DW. 1992. Mechanisms of obstructive sleep apnea. Chest, 101:541-9.
82. Imagawa S, Yamaguchi Y, Ogawa K, et al. 2004. Interleukin-6 and tumor necrosis factor-alpha in patients with obstructive sleep apnea-hypopnea syndrome. Respiration, 71:24-9.
83. Ip MS, Lam KS, Ho C, et al. 2000. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest, 118:580-6.
84. Ip MS, Tse HF, Lam B, et al. 2004. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med, 169:348-53.
85. Kessler R, Chaouat A, Weitzenblum E, et al. 1996. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J, 9:787-94.
86. Kokturk O, Ciftci TU, Mollarecep E, et al. 2005. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J, 46:801-9.
87. Krimsky WR, Leiter JC. 2005. Physiology of breathing and respiratory control during sleep. Semin Respir Crit Care Med, 26:5-12.
88. Kushida CA, Littner MR, Morgenthaler T, et al. 2005. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep, 28:499-521.
89. Laks L, Lehrhaft B, Grunstein RR, et al. 1995. Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J, 8:537-41.
90. Lattimore JL, Wilcox I, Skilton M, et al. 2006. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax, 61:491-5.
91. Leech JA, Goal E, Baer P, et al. 1987. Determinants of hypercapnia in occlusive sleep apnea syndrome. Chest, 92:807-13.
92. Lewis CA, Eaton TE, Fergusson W, et al. 2003. Home overnight pulse oximetry in patients with COPD: more than one recording may be needed. Chest, 123:1127-33.
93. Liistro G. 2002. Pathophysiology of upper airway obstruction during sleep. Acta Otorhinolaryngol Belg, 56:101-6.
94. Lin CC. 1994. Effect of nasal CPAP on ventilatory drive in normocapnic and hypercapnic patients with obstructive sleep apnoea syndrome. Eur Respir J, 7:2005-10.
95. Lindberg A, Jonsson AC, Ronmark E, et al. 2005. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration, 72:471-9.
96. Lindstrom M, Jonsson B, Larsson K, et al. 2002. Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis, 6:76-84.
97. Liu H, Liu J, Xiong S, et al. 2000. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. J Tongji Med Univ, 20:200-2.
98. Loube DI, Loube AA, Mitler MM. 1994. Weight loss for obstructive sleep apnea: the optimal therapy for obese patients. J Am Diet Assoc, 94:1291-5.
99. Louw SJ, Goldin JG, Joubert G. 1996. Spirometry of healthy adult South African men. Part I. Normative values. S Afr Med J, 86:814-9.
100. Lugaresi E, Coccagna G, Mantovani M, et al. 1972. Some periodic phenomena arising during drowsiness and sleep in man. Electroencephalogr Clin Neurophysiol, 32:701-5.
101. Man GC, Champman KR, Ali SH, et al. 1996. Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Chest, 110:648-53.
102. Man SF, Connett JE, Anthonisen NR, et al. 2006. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax, 61:849-53.
103. Mansfield D, Naughton MT. 1999. Effects of continuous positive airway pressure on lung function in patients with chronic obstructive pulmonary disease and sleep disordered breathing. Respirology, 4:365-70.
104. Marin JM, Carrizo SJ, Vicente E, et al. 2005. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet, 365:1046-53.
105. Marshall NS, Barnes M, Travier N, et al. 2006. Continuous positive airway pressure reduces daytime sleepiness in mild to moderate obstructive sleep apnoea: a meta-analysis. Thorax, 61:430-4.
106. Martin RJ, Bartelson BL, Smith P, et al. 1999. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest, 115:1338-45.
107. McKeon JL, Murree-Allen K, Saunders NA. 1989. Supplemental oxygen and quality of sleep in patients with chronic obstructive lung disease. Thorax, 44:184-8.
108. McNicholas WT, Calverley PM, Lee A, et al. 2004. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J, 23:825-31.
109. Millman RP, Knight H, Kline LR, et al. 1988. Changes in compartmental ventilation in association with eye movements during REM sleep. J Appl Physiol, 65:1196-202.
110. Minoguchi K, Tazaki T, Yokoe T, et al. 2004. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest, 126:1473-9.
111. Morrell MJ, Harty HR, Adams L, et al. 1995. Changes in total pulmonary resistance and PCO2 between wakefulness and sleep in normal human subjects. J Appl Physiol, 78:1339-49.
112. Muller NL, Francis PW, Gurwitz D, et al. 1980. Mechanism of hemoglobin desaturation during rapid-eye-movement sleep in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis, 121:463-9.
113. Mulloy E, McNicholas WT. 1996. Ventilation and gas exchange during sleep and exercise in severe COPD. Chest, 109:387-94.
114. Nieto FJ, Herrington DM, Redline S, et al. 2004. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med, 169:354-60.
115. Nieto FJ, Young TB, Lind BK, et al. 2000. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA, 283:1829-36.
116. O'Brien A, Whitman K. 2005. Lack of benefit of continuous positive airway pressure on lung function in patients with overlap syndrome. Lung, 183:389-404.
117. Oflaz H, Cuhadaroglu C, Pamukcu B, et al. 2006. Endothelial function in patients with obstructive sleep apnea syndrome but without hypertension. Respiration, 73:751-56
118. Ohga E, Nagase T, Tomita T, et al. 1999. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol, 87:10-4.
119. Orr WC, Shamma-Othman Z, Levin D, et al. 1990. Persistent hypoxemia and excessive daytime sleepiness in chronic obstructive pulmonary disease (COPD). Chest, 97:583-5.
120. Ozturk L, Unal M, Tamer L, et al. 2003. The association of the severity of obstructive sleep apnea with plasma leptin levels. Arch Otolaryngol Head Neck Surg, 129:538-40.
121. Patel SR, White DP, Malhotra A, et al. 2003. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med, 163:565-71.
122. Pauwels RA, Buist AS, Ma P, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care, 46:798-825.
123. Peker Y, Hedner J, Norum J, et al. 2002. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med, 166:159-65.
124. Peña VS, Miravitlles M, Gabriel R, et al. 2000. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest, 118:981-9.
125. Phillipson EA. 1978. Control of breathing during sleep. Am Rev Respir Dis, 118:909-39.
126. Pichel F, Zamarron C, Magan F, et al. 2004. Health-related quality of life in patients with obstructive sleep apnea: effects of long-term positive airway pressure treatment. Respir Med, 98:968-76.
127. Pinto-Plata VM, Mullerova H, Toso JF, et al. 2006. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax, 61:23-8.
128. Radwan L, Maszczyk Z, Koziorowski A, et al. 1995. Control of breathing in obstructive sleep apnoea and in patients with the overlap syndrome. Eur Respir J, 8:542-5.
129. Ramsey SD, Sullivan SD. 2003. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl, 41:29-35.
130. Redline S, Kirchner HL, Quan SF, et al. 2004. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch Intern Med, 164:406-18.
131. Redline S, Leitner J, Arnold J, et al. 1997. Ventilatory-control abnormalities in familial sleep apnea. Am J Respir Crit Care Med, 156:155-60.
132. Redline S, Strohl KP. 1998. Recognition and consequences of obstructive sleep apnea hypopnea syndrome. Clin Chest Med, 19:1-19.
133. Resta O, Foschino-Barbaro MP, Bonfitto P, et al. 2000. Prevalence and mechanisms of diurnal hypercapnia in a sample of morbidly obese subjects with obstructive sleep apnoea. Respir Med, 94:240-6.
134. Ridker PM, Wilson PW, Grundy SM. 2004. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation, 109:2818-25.
135. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-26.
136. Rutter MK, Meigs JB, Sullivan LM, et al. 2004. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation, 110:380-5.
137. Saaresranta T, Irjala K, Aittokallio T, et al. 2005. Sleep quality, daytime sleepiness and fasting insulin levels in women with chronic obstructive pulmonary disease. Respir Med, 99:856-63.
138. Sajkov D, Wang T, Saunders NA, et al. 1999. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am J Respir Crit Care Med, 159:1518-26.
139. Sampol G, Sagales MT, Roca A, et al. 1996. Nasal continuous positive airway pressure with supplemental oxygen in coexistent sleep apnoea-hypopnoea syndrome and severe chronic obstructive pulmonary disease. Eur Respir J, 9:111-6.
140. Sandek K, Andersson T, Bratel T, et al. 1999. Sleep quality, carbon dioxide responsiveness and hypoxaemic patterns in nocturnal hypoxaemia due to chronic obstructive pulmonary disease (COPD) without daytime hypoxaemia. Respir Med, 93:79-87.
141. Sanders MH, Newman AB, Haggerty CL, et al. 2003. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med, 167:7-14.
142. Sanner BM, Doberauer C, Konermann M, et al. 1997. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med, 157:2483-7.
143. Schols AM, Creutzberg EC, Buurman WA, et al. 1999. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 160:1220-6.
144. Seneviratne U, Puvanendran K. 2004. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med, 5:339-43.
145. Series F, Cormier Y, Desmeules M, et al. 1989. Effects of respiratory drive on upper airways in sleep apnea patients and normal subjects. J Appl Physiol, 67:973-9.
146. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. 2002. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation, 105:2462-4.
147. Shimizu K, Chin K, Nakamura T, et al. 2002. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax, 57:429-34.
148. Simonds AK, Parker RA, Branthwaite MA. 1989. The effect of intermittent positive-pressure hyperinflation in restrictive chest wall disease. Respiration, 55:136-43.
149. Sin DD, Man SF. 2003. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation, 107:1514-9.
150. Somers VK, Mark AL, Abboud FM. 1988. Sympathetic activation by hypoxia and hypercapnia - implications for sleep apnea. Clin Exp Hypertens A, 10:413-22.
151. Soto Campos JG, Cano GS, Fernandez GJ, et al. 1996. Hypercapnic stimulation and ventilation response in the syndrome of sleep obstructive apnea. Comparison of reinhalation and steady state. Arch Bronconeumol, 32:341-7.
152. Steens RD, Pouliot Z, Millar TW, et al. 1993.Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep, 16:318-26.
153. Takabatake N, Nakamura H, Abe S, et al. 2000. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1179-84.
154. Tangel DJ, Mezzanotte WS, Sandberg EJ, et al. 1992. Influences of NREM sleep on the activity of tonic vs inspiratory phasic muscles in normal men. J Appl Physiol, 73:1058-66.
155. Tatsumi K, Kimura H, Kunitomo F, et al. 1986. Sleep arterial oxygen desaturation and chemical control of breathing during wakefulness in COPD. Chest, 90:68-73.
156. Weitzenblum E, Chaouat A. 2004. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev, 8:281-94.
157. Wellman A, Jordan AS, Malhotra A, et al. 2004. Ventilatory control and airway anatomy in obstructive sleep apnea. Am J Respir Crit Care Med, 170:1225-32.
158. White DP, Weil JV, Zwillich CW. 1985. Metabolic rate and breathing during sleep. J Appl Physio, 59:384-91.
159. Whitelaw WA, Brant RF, Flemons WW. 2005. Clinical usefulness of home oximetry compared with polysomnography for assessment of sleep apnea. Am J Respir Crit Care Med, 171:188-93.
160. Wiegand DA, Latz B, Zwillich CW, et al. 1990. Geniohyoid muscle activity in normal men during wakefulness and sleep. J Appl Physiol, 69:1262-9.
161. Wiegand L, Zwillich CW, Wiegand D, et al. 1991. Changes in upper airway muscle activation and ventilation during phasic REM sleep in normal men. J Appl Physiol, 71:488-97.
162. Wiegand L, Zwillich CW. 1994. Obstructive sleep apnea. Dis Mon, 40:197-252.
163. Wiegand L. 1990. Sleep and resistive loading influences on human upper airway collapsibility. Prog Clin Biol Res, 345:157-66.
164. Wijkstra PJ, Lacasse Y, Guyatt GH, et al. 2003. A meta-analysis of nocturnal noninvasive positive pressure ventilation in patients with stable COPD. Chest, 124:337-43.
165. Wright JL, Levy RD, Churg A. 2005. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax, 60:605-9.
166. Yende S, Waterer GW, Tolley EA, et al. 2006. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax, 61:10-6.
167. Yokoe T, Minoguchi K, Matsuo H, et al. 2003. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation, 107:1129-34.
168. Younes M, Ostrowski M, Thompson W, et al. 2001. Chemical control stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med, 163:1181-90.
169. Young T, Palta M, Dempsey J, et al. 1993. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med, 328:1230-5.
170. Zamarron C, Gude F, Barcala J, et al. 2003. Utility of oxygen saturation and heart rate spectral analysis obtained from pulse oximetric recordings in the diagnosis of sleep apnea syndrome. Chest, 123:1567-76.
171. Zamarron C, Gude F, Otero Y, et al. 1998. Symptoms of sleep apnea syndrome in the general population. Arch Bronconeumol, 34:245-9.
172. Zamarron C, Gude F, Otero Y, et al. 1999. Prevalence of sleep disordered breathing and sleep apnea in 50- to 70-year-old individuals. A survey. Respiration, 66:317-22.
173. Zamarron-Sanz C, Ricoy-Galbaldon J, Gude-Sampedro F, et al. 2006. Plasma levels of vascular endothelial markers in obstructive sleep apnea. Arch Med Res, 37:552-5.
174. Zouaoui BK, Van MA, Doumit S, et al. 2006. Sleep apnoea-hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration, 73:243-6.